Integra LifeSciences Holdings Corporation

Second-quarter revenue was $419 million, up 0.8% reported and 0.7% organic. Adjusted EPS was $0.56, up 24% from the prior year and above the high end of guidance; management said tariff favorability contributed about $0.05 per share. Gross margin was 61.3%, up about 60 basis points from 60.7%, and adjusted EBITDA margin was 18.7%, up about 160 basis points from 17.1%. Specialty Surgery revenue was $309.3 million, up 1.7% reported and 1.6% organic, while Tissue Reconstruction revenue was $109.5 million, down 1.9% reported and 2% organic. For Q3, revenue is expected to be $410 million to $425 million and adjusted EPS $0.53 to $0.61. For full-year 2026, organic revenue growth is reaffirmed at 0.8% to 3.3%, reported revenue is now expected at $1.654 billion to $1.695 billion, and adjusted EPS remains $2.40 to $2.50.

Stuart Essig said the quarter showed better consistency, stronger execution, and important operational milestones, with supply reliability improving and the organization becoming more aligned. He emphasized that Integra does not need a strategic reset, but rather better execution, simplification, and deeper customer and hospital engagement. He highlighted the relaunch of PriMatrix, the planned fourth-quarter SurgiMend relaunch, and the broader PMA strategy in breast reconstruction as key long-term growth opportunities.

Lea Daniels Knight focused on the quarter’s financial improvement and guidance framework. She cited revenue of $419 million, adjusted EPS of $0.56, gross margin of 61.3%, adjusted EBITDA margin of 18.7%, operating cash flow of $22.8 million, free cash flow of $10.5 million, net debt of $1.6 billion, and leverage of 4.1x. She said full-year operating cash flow should improve by about $150 million, helped by about $60 million of reduced EU MDR and Braintree start-up cash costs, and noted expected 2026 cost savings of $25 million to $30 million plus an additional $10 million to $15 million on an annualized basis in 2027. She also said the company expects to refinance bank debt in the second half of 2026 if market conditions permit, with higher interest expense expected then but offset by tariff favorability.

Analysts pressed on why full-year EPS guidance was unchanged despite the Q2 beat; management said the quarter benefited from about $0.05 per share of tariff favorability, and that expected second-half higher interest expense from a planned refinancing will absorb that upside. Questions also centered on commercial execution, with management saying the new structure is about accountability, faster decisions, broader enterprise contracting, and leveraging GPO/IDN relationships into tissue reconstruction and ENT. On wound reconstruction and future product launches, management said PriMatrix is recovering to a little over 50% of pre-recall levels after roughly nine months, SurgiMend is expected to launch in Q4 with no meaningful 2026 contribution assumed, and MediHoney is targeted to return in 2027; analysts also asked about ENT reimbursement pressure, and management said full-year ENT is still expected to decline.